Get started
Author

Adriana Milillo

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors
2021 · Luis E. Raez, Kathleen Danenberg, et al. · Cancer Drug Resistance · 12
PDF
Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.
2023 · Kai He, David Paul Carbone, et al. · Journal of Clinical Oncology · 7
PDF
Is a Recent Episode of Diverticulitis an Acceptable Indication for Colonoscopy?
2004 · Pascale Anglade, Daniel Gelrud, et al. · Gastrointestinal Endoscopy · 4
RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes.
2019 · Luis E. Raez, Joshua L. Usher, et al. · Journal of Clinical Oncology · 1
Abstract P5-08-03: Significant overall survival (OS) benefit among patients with neoadjuvant chemotherapy use in T1c N0 triple negative and HER2 positive early breast cancer: a large National Cancer Database (NCDB) analysis
2025 · Amalia M. Bonano-Rios, Shenae Samuels, et al. · Clinical Cancer Research
Abstract OT3-03-01: Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer
2019 · H Han, E Hamilton, et al. · Cancer Research
Abstract P2-02-16: Use of cell-free circulating RNA and expression of PD-L1 and HER2 in plasma to monitor and predict clinical response in metastatic breast cancer patients
2018 · AB Castrellon, M Velez, et al. · Cancer Research
Works count: 7
Citation count: 24
H-index: 3
I10-index: 1
Year
Topic
Type